Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^®.

ABSTRACT:

Objective

It is well established that higher low-density lipoprotein (LDL)-cholesterol levels are associated with increased cardiovascular risk. We analyzed whether effects of empagliflozin on cardiovascular outcomes varied by different LDL-cholesterol levels at baseline in EMPA-REG OUTCOME.

Methods

Participants with type 2 diabetes and high cardiovascular risk received empagliflozin (10/25?mg) or placebo in addition to standard of care. We investigated the time to first 3P-MACE, cardiovascular death, hospitalization for heart failure (HHF) and all-cause mortality for empagliflozin versus placebo between baseline LDL-cholesterol categories <1.8, 1.8-<2.2, 2.2- <2.6, 2.6-3.0, and > 3.0?mmol/L, by a Cox regression including the interaction of baseline LDL-cholesterol category and treatment.

Results

Of the 7020 participants randomized and treated, 81.0% received lipid lowering therapy (77.0% statins). Mean ± SD LDL-cholesterol was 2.2 ± 0.9?mmol/L, and 38%/18%, had LDL-cholesterol <1.8/>3.0?mmol/L. Age, BMI, and HbA1c levels were balanced between the LDL-cholesterol subgroups, but those in the lowest versus highest group, had more coronary artery disease (83.0% vs 59.9%) and statin treatment (88.2% vs 50.9%). Empagliflozin consistently reduced all outcomes across LDL-cholesterol categories (all interaction p-values > 0.05).

Conclusion

The beneficial cardiovascular effects of empagliflozin was consistent across higher and lower LDL-cholesterol levels at baseline.

SUBMITTER: Langslet G 

PROVIDER: S-EPMC7919220 | biostudies-literature | 2020 Nov-Dec

REPOSITORIES: biostudies-literature